Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21667954 | 1.00 | MEN1 (0.47) | MEN1KMT2ASLC2A1KDM4CLPAR3 | |
| SCHEMBL10486013 | 1.00 | MEN1 (0.47) | MEN1KMT2ASLC2A1KDM4CLPAR3 | |
| SCHEMBL8459105 | 1.00 | MEN1 (0.47) | MEN1KMT2ASLC2A1KDM4CLPAR3 | |
| SCHEMBL16264036 | 1.00 | MEN1 (0.47) | MEN1KMT2ASLC2A1KDM4CLPAR3 | |
| SCHEMBL9732197 | 0.98 | MEN1 (0.45) | MEN1KMT2ASLC2A1KDM4CLPAR3 | |
| SCHEMBL10486622 | 0.95 | MEN1 (0.45) | MEN1KMT2ASLC2A1KDM4CL3MBTL1 | |
| SCHEMBL14363514 | 0.95 | MEN1 (0.45) | MEN1KMT2ASLC2A1KDM4CL3MBTL1 | |
| SCHEMBL20429037 | 0.90 | MEN1 (0.40) | MEN1KMT2ASLC2A1KDM4CL3MBTL1 | |
| SCHEMBL11917953 | 0.89 | MEN1 (0.43) | MEN1KMT2ASLC2A1KDM4CL3MBTL1 | |
| SCHEMBL19331641 | 0.88 | MEN1 (0.41) | MEN1KMT2ASLC2A1KDM4CL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155505-B2 | Synthesis of pheromones and related materials via olefin metathesis | PROVIVI, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200039900-A1 | SYNTHESIS OF PHEROMONES AND RELATED MATERIALS VIA OLEFIN METATHESIS | PROVIVI, INC. (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039900-A1 | SYNTHESIS OF PHEROMONES AND RELATED MATERIALS VIA OLEFIN METATHESIS | OSBPL8, CYP51A1, ERG28 | MEN1 39/4885KMT2A 4303/4885SLC2A1 4836/4885 |
| US-11155505-B2 | Synthesis of pheromones and related materials via olefin metathesis | OSBPL8, CYP51A1, ERG28 | MEN1 39/4885KMT2A 4303/4885SLC2A1 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.